Deciphera reports data analysis from Phase 1 clinical trial of DCC-2618
Deciphera Pharmaceuticals announced the presentation of data analysis from its ongoing Phase 1 clinical trial of DCC-2618, the Company's pan-KIT and PDGFRalpha inhibitor. The analysis and update was presented at the Annual Meeting of The Connective Tissue Oncology Society, or CTOS, on November 10, 2017, in Maui, HI, USA. The presentation reviews data from the same trial presented at the European Society for Medical Oncology, or ESMO, 2017 Congress in September 2017, and provides pharmacodynamic support for the recommended dose of 150 mg once daily. As reported at ESMO, the data showed that in heavily pretreated patients with gastrointestinal stromal tumorsm or GIST, treatment with DCC-2618 at greater than 100 mg daily resulted in disease control rates of 76% at 12 weeks and 57% at 24 weeks. Deciphera also provided an update on enrollment of the ongoing Phase 1 clinical trial announcing that as of October 31, 2017, a total of 125 patients had been dosed with DCC-2618 of which 109 were GIST patients, including 54 GIST patients in three expansion cohorts of the Phase 1 trial, which are enrolling 2nd-line, 3rd-line, and fourth-to-fifth line GIST patients, respectively. "The analysis presented at CTOS supports the selection of 150 mg once daily as the recommend dose and supports the planned evaluation of DCC-2618 in a placebo-controlled, randomized, pivotal Phase 3 trial in patients with GIST, who have previously failed all three approved therapies," said Michael Taylor, Ph.D., President and CEO of Deciphera Pharmaceuticals. "There are no approved therapies for these fourth-line GIST patients and new treatment options are desperately needed."